Med Ed Report briefs: November 2012

Med Ed Report briefs: November 2012
Med Ed Report briefs: November 2012

WebMD Health launched Medscape Germany ( to provide education tailored to the needs of German physicians and HCPs. It will be available to more than 300,000 doctors, offering registered users free, unlimited access to clinical information and resources, WebMD said.

Aligning with international rules, Ireland's Medical Council has moved to bar drugmakers from sending physicians to medical meetings, the Irish Times reported. Companies can still offer grants to groups that host such meetings as a way to help finance trips.

The Accreditation Council for Graduate Medical Education (ACGME) is starting an international program to raise GME standards in other countries, reported. ACGME-International just finished the first phase of a partnership with the Singapore health ministry to overhaul its GME accreditation system.

Diagnostic firm Simbionix USA is launching a simulator designed to offer hands-on training for ultrasound exams and interventions. The simulator will be shown for the first time at the upcoming American College of Emergency Physicians (ACEP) Exhibition in Denver, Colorado.
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.